🇺🇸 FDA

Company profile · Sponsor

ADC

ADC Therapeutics SA

ADCT · NYSE pharma EPALINGES, V8, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

ADC (ADCT) is a pharma company. headquartered in EPALINGES, V8, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker ADCT
Exchange NYSE
Company type pharma
Headquarters EPALINGES, V8, USA
SEC CIK 0001771910

Pipeline (24)

Search pipeline →

  1. Loncastuximab Tesirine

    ADC

    Relapsed Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  2. Odronextamab

    ADC

    B-cell Non Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  3. ADCT-301

    ADC

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  4. ADCT-602

    ADC

    Blasts 5 Percent or More of Bone Marrow Nucleated Cells

    phase 2 mab terminated

    1 trial

  5. Camidanlumab Tesirine

    ADC

    Relapsed Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  6. Cyclophosphamide

    ADC

    Double-Expressor Lymphoma

    phase 2 small molecule active

    1 trial

  7. Epcoritamab

    ADC

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. Loncastuximab Tesirine

    ADC

    Relapsed Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  9. Loncastuximab Tesirine

    ADC

    Relapsed or Refractory Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  10. Loncastuximab Tesirine

    ADC

    Waldenstrom Macroglobulinemia

    phase 2 small molecule active

    1 trial

  11. Loncastuximab Tesirine

    ADC

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    4 trials

  12. Loncastuximab tesirine

    ADC

    Post-transplant Lymphoproliferative Disorder

    phase 2 small molecule active

    1 trial

  13. Loncastuximab tesirine

    ADC

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  14. Loncastuximab tesirine

    ADC

    Diffuse Large B-Cell Lymphoma Refractory

    phase 2 small molecule completed

    1 trial

  15. Loncastuximab tesirine 150 µg/Kg

    ADC

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  16. imvotamab

    ADC

    Non-Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  17. A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

    ADC

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  18. ADCT-301

    ADC

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  19. ADCT-301

    ADC

    Head and Neck Cancer Squamous Cell Carcinoma

    phase 1 small molecule terminated

    1 trial

  20. ADCT-402

    ADC

    Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  21. ADCT-402

    ADC

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  22. ADCT-502

    ADC

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  23. ADCT-601

    ADC

    Advanced Solid Tumors

    phase 1 small molecule terminated

    2 trials

  24. ADCT-901

    ADC

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. loncastuximab tesirine-lpyl

    ZYNLONTA

    INJECTION approved

Patents (8)

Search patents →

  1. US 11976122

    Anti-IL13Rα2 antibodies

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11938192

    Dosage regimes for the administration of an anti-CD19 ADC

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11813335

    Pyrrolobenzodiazepine-antibody conjugates

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11702473

    Site-specific antibody-drug conjugates

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11690918

    Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11596696

    Combination therapy with an anti-CD25 antibody-drug conjugate

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11426467

    Dosage regimes for the administration of an anti-CD25 ADC

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11384098

    Pyrrolobenzodiazepine-antibody conjugates

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ADC?

ADC (ADCT) is a pharma company. headquartered in EPALINGES, V8, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does ADC sponsor?

We track 24 ClinicalTrials.gov-linked programs for ADC, including Loncastuximab Tesirine and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ADC company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.